Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein

Journal of Virology

Volumn 76, Issue 19, 2002, Pages 9888-9899

  Xiang, Shi Hua ^a   Kwong, Peter D ^a   Gupta, Rishi ^a   Rizzuto, Carlo D ^a   Casper, David J ^a   Wyatt, Richard ^a   Wang, Liping ^a   Hendrickson, Wayne A ^a   Doyle, Michael L ^a   Sodroski, Joseph ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; INDOLE; PHENYLALANINE; TRYPTOPHAN;

ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; ENTROPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; X RAY CRYSTALLOGRAPHY;

ANTIGENS, CD4; CELL LINE; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MODELS, STRUCTURAL; MUTAGENESIS; PROTEIN CONFORMATION; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 0036776445     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.19.9888-9899.2002     Document Type: Article

References (102)

1. Conformational stabilities of Escherichia coli RNase HI variants with a series of amino acid substitutions at a cavity within the hydrophobic core
2. Receptor-mediated activation of immunodeficiency viruses in viral fusion
3. Identification of the residues in human CD4 critical for the binding of HIV
4. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
5. HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 coreceptor
6. Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120
7. Analysis of the site in CD4 that binds to the HIV envelope glycoprotein
8. Structural and energetic responses to cavity-creating mutations in hydrophobic cores: Observation of a buried water molecule and the hydrophilic nature of such hydrophobic cavities
9. A vaccine for HIV type 1: The antibody perspective
10. The antibody response in HIV-1 infection
11. Why do we not have an HIV vaccine and how can we make one?
12. Identification of HIV1 determinants for T lymphoid cell line infection
13. Core structure of gp41 from the HIV envelope glycoprotein
14. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
15. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
16. Single amino-acid changes in HIV envelope affect viral tropism and receptor binding
17. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
18. Identification of a major co-receptor for primary isolates of HIV-1
19. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors
20. Thermodynamic analysis of cavity creating mutations in an engineered leucine zipper and energetics of glycerol-induced coiled coil stabilization
21. Similar hydrophobic replacements of Leu99 and Phe153 within the core of T4 lysozyme have different structural and thermodynamic consequences
22. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
23. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
24. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
25. Vaccines and immunology: Elucidating immunity to HIV-1 and current prospects for AIDS vaccine development
26. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1
27. Stabilization of Escherichia coli ribonuclease HI by cavity-filling mutations within a hydrophobic core
28. A single amino acid substitution can restore the solubility of aggregated colicin A mutants in Escherichia coli
29. Effect of cavity-creating mutations in the hydrophobic core of chymotrypsin inhibitor 2
30. Contribution of hydrophobic interactions to protein stability
31. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
32. Challenges in the development of an effective HIV vaccine: Current approaches and future directions
33. Properties of the protein matrix revealed by the free energy of cavity formation
34. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops
35. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication
36. Stability analysis for the cavity-filling mutations of the Myb DNA-binding domain utilizing free-energy calculations
37. Numbering positions in HIV relative to HXBc2
38. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
39. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
40. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor
41. Filling a cavity dramatically increases pressure stability of the c-Myb R2 subdomain
42. Theoretical studies of the response of a protein structure to cavity-creating mutations
43. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells
44. Progress in the development of an HIV-1 vaccine
45. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein
46. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions
47. The human immunodeficiency virus gp120 binding site on CD4: Delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure
48. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies
49. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
50. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans
51. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by with monoclonal antibodies
52. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies
53. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains
54. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
55. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism
56. Energetics of the HIV gp120-CD4 binding reaction
57. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
58. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain
59. Stabilization of hen egg white lysozyme by a cavity-filling mutation
60. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding
61. How to measure and predict the molar absorption coefficient of a protein
62. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
63. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
64. Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4
65. Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region
66. Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes
67. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection
68. Evaluating the energetics of empty cavities and internal mutations in proteins
69. Thermodynamic and structural studies of cavity formation in proteins suggest that loss of packing interactions rather than the hydrophobic effect dominates the observed energetics
70. The interpretation of protein structures: Total volume, group volume distributions and packing density
71. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120
72. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
73. Crystal structure of an HIV-binding recombinant fragment of human CD4
74. Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design
75. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
76. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding
77. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1
78. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys
79. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop
80. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS
81. Effects of cavity-creating mutations on conformational stability and structure of the dimeric 4-alphahelical protein ROP: Thermal unfolding studies
82. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120
83. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies
84. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell-line-passaged human immunodeficiency virus type 1 isolates
85. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody
86. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein
87. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
88. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody
89. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5
90. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
91. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains
92. Atomic structure of the ectodomain from HIV-1 gp41
93. Dimeric association and segmental variability in the structure of human CD4
94. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
95. The antigenic structure of the HIV gp120 envelope glycoprotein
96. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding
97. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
98. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions
99. Characterization of CD4-induced epitopes on the HIV-1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies
100. A cavity-forming mutation in insulin induces segmental unfolding of a surrounding alpha-helix
101. The crystal structure of the SIV gp41 ectodomain at 1.47 Å resolution
102. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo